{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ZVRA",
  "name": "Zevra Therapeutics, Inc.",
  "url": "https://orbyd.app/dossiers/ZVRA/",
  "json_url": "https://orbyd.app/dossiers/ZVRA.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "The June patent re-rating fully reversed: EMA's CHMP issued a negative opinion on arimoclomol's EU application 2026-07-24 (efficacy not proven), and ZVRA gapped ~24% to the high-$9s, cutting through the $11.50 base. EU expansion is now blocked pending a re-examination that won't resolve before Q4; no accelerating narrative remains, and the next binary is the early-August Q2 print.",
  "invalidation_trigger": "A daily close below $8.52 (loses the 2026-07-24 CHMP-selloff low) confirms the de-rating extending toward the $7.16 52-week low and kills any basing thesis; secondarily, a Q2 print in early August with MIPLYFFA net revenue below Q1's $24.6M would confirm the sole US revenue engine stalling.",
  "catalyst_date": "2026-08-06",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "rare-disease-gene-therapy",
    "binary-catalyst-biotech",
    "precision-biotech-therapeutics"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "2026-07-24: EMA CHMP negative opinion on arimoclomol MAA for NPC (efficacy not sufficiently proven). Company to request re-examination; grounds typically due ~60 days, outcome likely Q4 2026+. Global Expanded Access Program continues collecting real-world evidence.",
    "US franchise unaffected: MIPLYFFA FDA-approved September 2024, on-market and generating revenue; the setback is EU-only.",
    "Single-drug concentration: MIPLYFFA was >82% of 2025 revenue ($87.4M of $106.5M); NPC is ultra-rare (a few hundred treated US patients).",
    "Q1 2026: total net revenue $36.2M (+78% YoY), MIPLYFFA net revenue $24.6M; adjusted net income ~$11.5M, adjusted EPS $0.18 vs $0.06 consensus; GAAP net income $37.9M flattered by a $43.3M one-time SDX gain.",
    "Balance sheet: $236.8M cash at 2026-03-31, debt-free after $63.1M term-loan prepayment and $50M SDX-portfolio sale to Commave. ~40% of post-crash market cap is cash.",
    "US exclusivity intact: Orange Book patent 11,707,456 (expiry 2041-11-19) listed 2026-06-08 plus USPTO PTE filing — unaffected by the EU rejection.",
    "Pre-CHMP sell-side targets (avg ~$28.33; HC Wainwright Buy $26 on 2026-06-23) are now stale and likely to be cut.",
    "Earnings blackout: next print (Q2 2026) ~early August 2026, est. 2026-08-06 — re-confirm date. Watch MIPLYFFA net revenue vs $24.6M, cash burn, payer access (~69% of covered lives), EU re-examination commentary.",
    "Pipeline optionality: celiprolol Phase 3 (DiSCOVER, vEDS) FDA meeting guided 2H 2026 — binary, beyond 30-day window."
  ],
  "body_markdown": "## Current Thesis\nThe momentum re-rating that defined this name in June is over. On 2026-07-24 the EMA's Committee for Medicinal Products for Human Use (CHMP) adopted a negative opinion on the marketing application for arimoclomol in Niemann-Pick disease type C, ruling efficacy had not been sufficiently demonstrated. The stock gapped roughly 24% lower — intraday range $8.52 to $11.59, closing near $9.47 — cutting straight through the $11.50 base that had held since the June patent listing and giving back every point of the re-rating plus the pre-news shelf near $11. The narrative an investor was buying three weeks ago — a de-risked, cash-generative rare-disease asset re-rating toward ~$28 street targets — no longer exists. What remains is a US-only single-drug commercial company (MIPLYFFA, FDA-approved September 2024) whose European expansion path is now blocked pending a re-examination that, on standard CHMP timelines, will not resolve before Q4 2026. There is no accelerating leg to ride and no near-dated positive binary; the structure is broken and the next hard event is the Q2 print in early August. This is a stand-aside until it bases, not a dip to buy.\n\n## Bull Case\n- US franchise untouched: the CHMP opinion is EU-only. MIPLYFFA remains FDA-approved (September 2024), on-market, and generating revenue — Q1 2026 total net revenue $36.2M (+78% YoY), MIPLYFFA net revenue $24.6M, versus 2025 MIPLYFFA revenue of $87.4M against $10.1M in 2024.\n- Balance-sheet cushion under the selloff: $236.8M cash at 2026-03-31, debt-free after full prepayment of the $63.1M term loan and the $50M SDX-portfolio sale to Commave. Against a ~$586M market cap post-crash, roughly 40% of the cap is cash, limiting downside financing/dilution risk.\n- US exclusivity intact to 2041: Orange Book patent 11,707,456 (expiry 2041-11-19), listed 2026-06-08, plus the USPTO patent-term-extension filing — the EU rejection does not touch the domestic patent estate.\n- Optionality still on the board: celiprolol Phase 3 (DiSCOVER, vEDS) with an FDA meeting guided for 2H 2026, and a formal CHMP re-examination that could partially recover the EU thesis if new real-world evidence moves the panel.\n- Real underlying earnings power: Q1 2026 adjusted net income ~$11.5M and adjusted EPS $0.18 beat $0.06 consensus (GAAP net income of $37.9M was flattered by a $43.3M one-time SDX gain).\n\n## Bear Case\n- The binary just resolved against the story: the 2026-07-24 CHMP negative opinion removes the largest piece of forward optionality and does so on an efficacy question, which is the hardest kind of rejection to overturn on re-examination.\n- Structure is broken: the ~24% gap-down sliced through the $11.50 base and the pre-patent shelf near $11 in a single session, inverting the trend that ran from $7.16 to the $14.58 high. There is no higher low yet to trade against.\n- Single-drug concentration is now more acute: MIPLYFFA was >82% of 2025 revenue ($87.4M of $106.5M). NPC is ultra-rare (a few hundred treated US patients), the US pool is finite, and the EU market that would have widened the runway is now gated indefinitely.\n- Sell-side targets are stale: the ~$28.33 average and HC Wainwright's $26 (2026-06-23) were struck pre-CHMP and near the highs; expect downward revisions that remove the \"valuation gap\" support.\n- Catalyst vacuum with negative overhang: no positive dated event inside 30 days, while the re-examination process itself keeps the EU question open as a lingering headline risk into Q4.\n\n## Setup & Price Structure\nThe tape has fully inverted. Into 2026-07-24 the stock was consolidating in the mid-$14s to low-$12s; the CHMP news produced a ~24% single-day decline to roughly $9.47, with an intraday range of $8.52 to $11.59 and market cap compressing to ~$586M. That move erased the June patent-listing breakout and closed the stock below the $11 pre-news shelf — prior support is now overhead supply. Within the $7.16–$14.58 52-week range, price sits in the lower third with momentum broken and no confirmed higher low. First support is the 2026-07-24 selloff low at $8.52; below that, the next reference is the pre-June congestion and the $7.16 52-week low. Overhead, the reclaimed zone runs $11.00–$11.50, then the unfilled gap toward the low $12s. For a momentum book this is the opposite of a setup: a knife that just broke structure on a negative regulatory event. Averaging into weakness here is precisely the trap the playbook exists to avoid — the correct stance is to wait for a base and a higher low before considering any re-entry.\n\n## Catalyst Calendar (next 30 days)\n\n- ~2026-08-06 (est.): Q2 2026 earnings print — the next hard binary. Watch MIPLYFFA net revenue versus Q1's $24.6M, US payer access (was ~69% of covered lives), cash burn against the $236.8M base, and any management framing of the EU re-examination timeline and guidance impact.\n- No FDA/PDUFA date, and no scheduled celiprolol readout, falls inside the next 30 days; the DiSCOVER/vEDS FDA interaction is guided only to 2H 2026.\n\n## Elapsed catalysts\n\n- Ongoing (procedural, outcome beyond 30 days): CHMP re-examination request following the 2026-07-24 negative opinion — grounds are typically due within ~60 days, with a re-examination outcome likely in Q4 2026 or later. No decision inside this window. *(passed 9d ago)*\n\n## What Would Change Our Mind\n\n- Fundamental proof the US engine is intact: a Q2 print (early August) with MIPLYFFA net revenue meaningfully above $24.6M and unchanged-or-raised guidance would confirm that EU was always incremental optionality, not the core.\n- EU path revival: any procedural signal that the re-examination has a credible route — new real-world evidence accepted, scope narrowed — would restore part of the lost optionality.\n- Bearish confirmation to keep standing aside: a daily close below $8.52 confirms the de-rating extending toward the $7.16 52-week low; that keeps the name a pass until a genuinely new base and catalyst appear.\n\n## Correlation Notes\nThis is an idiosyncratic, single-asset rare-disease name driven by drug-specific regulatory and commercial events, not macro or index beta. It does not travel with the AI/quantum/momentum baskets; XBI/biotech beta is at most a weak secondary influence, and company-specific binaries dominate the variance. The 2026-07-24 CHMP efficacy ruling carries a modest negative read-through for other US-approved-but-EU-pending ultra-rare therapeutics that lean on small open-label datasets — the panel's efficacy bar is the shared risk. The heavy net-cash position ($236.8M, debt-free) mutes the financing/dilution correlation that punishes cash-burning small-cap biotech during risk-off, a relative cushion versus peers, though it does not offset event risk. Within NPC and lysosomal-disease competitors, the rejection is a mild positive read-through for rivals but does not change ZVRA's own broken-structure stance.",
  "first_seen": "2026-06-11",
  "last_analyzed": "2026-07-25T08:16:43+00:00",
  "last_synthesized": "2026-07-25",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}